A phase 2, multicentre, open‐label trial (ACE‐LY‐003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma

por Strati, Paolo, Coleman, Morton, Champion, Rebecca, Ma, Shuo, Patti, Caterina, Levy, Moshe Y., Lossos, Izidore S., Geethakumari, Praveen Ramakrishnan, Lam, Selay, Calvo, Roser, Higgins, Kara, Budde, Lihua E.
Publicado 2022

A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma

por Paul, Barry, Liedtke, Michaela, Khouri, Jack, Rifkin, Robert, Gandhi, Mitul D, Kin, Andrew, Levy, Moshe Y, Silbermann, Rebecca, Cottini, Francesca, Sborov, Douglas W, Sandhu, Irwindeep, Villarreal, Lyssa, Murphy, Michael, Gu, Lin, Chen, Ann, Rajakumaraswamy, Nishanthan, Usmani, Saad Z
Publicado 2023

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial

por Bahlis, Nizar J., Costello, Caitlin L., Raje, Noopur S., Levy, Moshe Y., Dholaria, Bhagirathbhai, Solh, Melhem, Tomasson, Michael H., Damore, Michael A., Jiang, Sibo, Basu, Cynthia, Skoura, Athanasia, Chan, Edward M., Trudel, Suzanne, Jakubowiak, Andrzej, Gasparetto, Cristina, Chu, Michael P., Dalovisio, Andrew, Sebag, Michael, Lesokhin, Alexander M.
Publicado 2023